Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 10/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | APP | P05067 | 1/20 | 0.57 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22146846 | 0.91 | TSHR (0.54) | FFAR1TSHRAPPFFAR4LTA4H | |
| SCHEMBL16624600 | 0.90 | TSHR (0.48) | FFAR1TSHRAPPFFAR4LTA4H | |
| SCHEMBL20717677 | 0.89 | TSHR (0.52) | FFAR1TSHRAPPFFAR4LTA4H | |
| SCHEMBL22146848 | 0.89 | TSHR (0.52) | FFAR1TSHRAPPFFAR4LTA4H | |
| SCHEMBL22146857 | 0.89 | TSHR (0.52) | FFAR1TSHRAPPFFAR4LTA4H | |
| SCHEMBL11771982 | 0.81 | FFAR1 (0.68) | FFAR1TSHRFFAR4 | |
| SCHEMBL1692261 | 0.81 | APP (0.54) | FFAR1TSHRAPPCYP2C19 | |
| SCHEMBL9454240 | 0.80 | FFAR1 (0.66) | FFAR1TSHRAPPFFAR4ASIC3 | |
| SCHEMBL17954218 | 0.79 | CYP2A6 (0.52) | FFAR1TSHRFFAR4 | |
| SCHEMBL2517886 | 0.79 | LOXL2 (0.52) | FFAR1TSHRAPPASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116425607-A | Method for preparing cis-form or trans-form alkene by chromium-catalyzed intermediate alkyne selective hydrogenation | 四川大学 | 2023-07-14 | — | — | CN | disclosed |
| CN-111378142-A | Force-induced response supramolecular polymer | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| US-20200199657-A1 | OPTICAL SUPER-MULTIPLEXING BY POLYYNES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2020-06-25 | — | — | US | disclosed |
| US-7312230-B2 | Carboxylic acid derivatives as IP antagonists | ROCHE PALO ALTO LLC (US) | 2007-12-25 | — | — | US | disclosed |
| US-7056903-B2 | Carboxylic acid derivatives as IP antagonists | SYNTEX (U.S.A.) LLC (US) | 2006-06-06 | — | — | US | disclosed |
| US-20060035870-A1 | 2-[4-(1H-Indol-4-yloxymethyl)-benzyloxycarbonylamino]-3-phenyl-propionic acid; 3-Phenyl-2-[4-(quinolin-5-yloxymethyl)-benzyloxycarbonylamino]-propionic acid; urinary tract, pain, inflammation, respiratory states, edema formation, or hypotensive vascular diseases | COURNOYER RICHARD L | 2006-02-16 | — | — | US | disclosed |
| US-6693098-B2 | CARBOXYLIC ACID OR TETRAZOLE DERIVATIVES CONTAINING CARBAMATE GROUPS ARE USEFUL FOR TREATING THE CONDITIONS ASSOCIATED WITH THE URINARY TRACT, PAIN, INFLAMMATION, RESPIRATORY STATES, EDEMA FORMATION OF HYPOTENSIVE VASCULAR DISEASES | SYNTEX (U.S.A) LLC | 2004-02-17 | — | — | US | disclosed |
| US-20030220367-A1 | Carboxylic acid derivatives as IP antagonists | COURNOYER RICHARD LEO (US) | 2003-11-27 | — | — | US | disclosed |
| EP-1265853-A1 | CARBOXYLIC ACID DERIVATIVES AS IP ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2002-12-18 | — | — | EP | disclosed |
| US-20010056100-A1 | Carboxylic acid derivatives as IP antagonists | SYNTEX (U.S.A.) LLC | 2001-12-27 | — | — | US | disclosed |
| WO-2001068591-A1 | CARBOXYLIC ACID DERIVATIVES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-20 | — | — | WO | disclosed |
| US-4042584-A | ENZYME INHIBITORS | MERCK & CO., INC. (US) | 1977-08-16 | — | — | US | disclosed |
| US-3957871-A | ANTIARRHYTHMIA AGENTS, UNSATURATED AROMATIC AMINES | MERCK & CO., INC. (US) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035870-A1 | 2-[4-(1H-Indol-4-yloxymethyl)-benzyloxycarbonylamino]-3-phenyl-propionic acid; 3-Phenyl-2-[4-(quinolin-5-yloxymethyl)-benzyloxycarbonylamino]-propionic acid; urinary tract, pain, inflammation, respiratory states, edema formation, or hypotensive vascular diseases | AGTR1, AGTR2, PTGIR | FFAR1 38/4885TSHR 620/4885APP 4232/4885 |
| US-20030220367-A1 | Carboxylic acid derivatives as IP antagonists | GABRP, GPBAR1, FFAR1 | FFAR1 3/4885TSHR 213/4885APP 4416/4885 |
| US-20010056100-A1 | Carboxylic acid derivatives as IP antagonists | GABRP, GPBAR1, FFAR1 | FFAR1 3/4885TSHR 192/4885APP 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.